Orano Med
Clinical-stage biotechnology company developing targeted alpha therapies against cancer using lead-212 (212Pb) radioisotopes, a subsidiary of the Orano Group.
- CEO / Founder
- Frédéric Desdouits
- Team Size
- 51-200
- Stage
- Growth Stage
- Total Funding
- $467.5M
- Latest Round
- Corporate Round
- Key Investors
- Sanofi; European Investment Bank (EIB); Orano Group
Technology & Products
Key Products
AlphaMedix (212Pb-DOTAMTATE) — Phase 2/3 for neuroendocrine tumors (licensed to Sanofi); 212Pb-GRPR — Phase 1 for solid tumors (breast, prostate, glioblastoma); 212Pb-CEA-PRIT — Phase 1 for colorectal cancer (collaboration with Roche); 212Pb-MP2050 — preclinical (collaboration with Molecular Partners)
Technological Advantage
Proprietary 212Pb production and purification technology; Macrocyclics subsidiary (acquired 2011) for chelating agent technology and antibody site-specific conjugation; world's first industrial-scale thorium-228 extraction facility (ATEF); 3 preclinical laboratories; 2 ongoing clinical trials
Differentiation
Value Proposition
Developing targeted alpha therapies (TAT) using lead-212 (212Pb), a rare alpha-emitting radioisotope, to precisely destroy cancer cells while limiting damage to surrounding healthy tissue.
How They Differentiate
End-to-end control of the lead-212 supply chain — from thorium-228 extraction (ATEF facility in France) to GMP pharmaceutical production (ATLabs in US and France) — ensuring reliable, scalable supply of 212Pb, a key bottleneck for the field. 18 patent families protecting production methods and conjugation technology. Breakthrough Therapy Designation from FDA for AlphaMedix.
Market & Competition
Target Customers
Pharmaceutical companies (licensing partners); oncology patients with rare cancers and high unmet medical needs; healthcare providers specializing in radiopharmaceutical therapies
Industry Verticals
Oncology; Nuclear Medicine; Radiopharmaceuticals; Biotechnology
Competitors
Actinium Pharmaceuticals (Ac-225 based TAT); Fusion Pharmaceuticals (acquired by AstraZeneca, Ac-225); NAYA Therapeutics; Eckert & Ziegler (Ac-225 and Pb-212 supply)
Growth & Milestones
Growth Metrics
230 employees (France and US); 18 patent families; 2 ongoing clinical trials; 3 preclinical laboratories; 1 industrial production platform for lead-212
Major Milestones
2009: Company founded as spinout from Areva (now Orano); 2011: Acquisition of Macrocyclics (chelating agent technology); 2020: First production of lead-212 by dissolution of thorium nitrate; 2023: FDA Breakthrough Therapy Designation for AlphaMedix; 2024: Exclusive licensing agreement with Sanofi/RadioMedix for AlphaMedix (€100M upfront); 2024: Sanofi invests €300M for ~16% stake (valuation €1.9B); 2025: Won Innovation of the Year award (L'Usine Nouvelle); 2026: EIB €125M loan for ATEF facility; 2026: Frédéric Desdouits appointed CEO
Notable Customers
Sanofi (licensing partner); Roche (collaboration partner)